Multi-target-directed ligands as innovative tools to combat trypanosomatid diseases

Current Topics in Medicinal Chemistry

Volumn 11, Issue 22, 2011, Pages 2824-2833

  Bolognesi, Maria Laura ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Combination therapy; Hybrid compounds; Leishmaniasis; Multitarget drug discovery; Neglected tropical diseases; Trypanosomiasis

Indexed keywords

ALENDRONIC ACID; AMPHOTERICIN B; EFLORNITHINE; MELARSOPROL; N (2 HYDROXYPROPYL)METHACRYLAMIDE; NAFTIFINE; NIFURTIMOX;

AFRICAN TRYPANOSOMIASIS; ARTICLE; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; MONOTHERAPY; NONHUMAN; TROPICAL DISEASE;

ANIMALS; HUMANS; LIGANDS; TRYPANOCIDAL AGENTS; TRYPANOSOMIASIS;

EID: 82055192215     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611798184391     Document Type: Article

References (64)

1. Hotez, P. J.; Molyneux, D. H.; Fenwick, A.; Kumaresan, J.; Sachs, S. E.; Sachs, J. D.; Savioli, L. Control of neglected tropical diseases. N. Engl. J. Med., 2007, 357, 1018-1027.
2. Hotez, P. J.; Kamath, A. Neglected tropical diseases in sub-Saharan Africa: Review of their prevalence, distribution, and disease burden. PLoS Negl. Trop. Dis., 2009, 3, e412.
3. Nwaka, S.; Ridley, R. G. Virtual drug discovery and development for neglected diseases through public-private partnerships. Nat. Rev. Drug. Discov., 2003, 2, 919-928.
4. Trouiller, P.; Olliaro, P.; Torreele, E.; Orbinski, J.; Laing, R.; Ford, N. Drug development for neglected diseases: A deficient market and a public-health policy failure. Lancet, 2002, 359, 2188-2194.
5. Kuepfer, I.; Burri, C. Reflections on clinical research in sub- Saharan Africa. Int. J. Parasitol., 2009, 39, 947-954.
6. Hopkins, A. L.; Witty, M. J.; Nwaka, S. Mission possible. Nature, 2007, 449, 166-169.
7. Caffrey, C. R.; Steverding, D. Recent initiatives and strategies to developing new drugs for tropical parasitic diseases Exp. Opin. Drug Discov., 2008, 3, 173-186.
8. Cavalli, A.; Bolognesi, M. L. Neglected tropical diseases: Multitarget- directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania. J. Med. Chem., 2009, 52, 7339-7359.
9. Cavalli, A.; Lizzi, F.; Bongarzone, S.; Belluti, F.; Piazzi, L.; Bolognesi, M. L. Complementary medicinal chemistry-driven strategies toward new antitrypanosomal and antileishmanial lead drug candidates. FEMS Immunol. Med. Microbiol., 2010, 58, 51-60.
10. Stuart, K.; Brun, R.; Croft, S.; Fairlamb, A.; Gurtler, R. E.; McKerrow, J.; Reed, S.; Tarleton, R. Kinetoplastids: Related protozoan pathogens, different diseases. J. Clin. Invest., 2008, 118, 1301-10.
11. Croft, S. L. Kinetoplastida: New therapeutic strategies. Parasite, 2008, 15, 522-527.
12. Nussbaum, K.; Honek, J.; Cadmus, C. M.; Efferth, T. Trypanosomatid parasites causing neglected diseases. Curr. Med. Chem., 2010, 17, 1594-617.
13. Sharlow, E. R.; Grogl, M.; Johnson, J.; Lazo, J. S. Anti-leishmanial drug discovery: Rising to the challenges of a highly neglected disease. Mol. Interv., 10, 72-75.
14. Chappuis, F.; Sundar, S.; Hailu, A.; Ghalib, H.; Rijal, S.; Peeling, R. W.; Alvar, J.; Boelaert, M. Visceral leishmaniasis: What are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol., 2007, 5, 873-882.
15. Alvar, J.; Aparicio, P.; Aseffa, A.; Den Boer, M.; Canavate, C.; Dedet, J. P.; Gradoni, L.; Ter Horst, R.; Lopez-Vélez, R.; Moreno, J. The relationship between leishmaniasis and AIDS: The second 10 years. Clin. Microbiol. Rev., 2008, 21, 334-359.
16. Barrett, M. P.; Burchmore, R. J.; Stich, A.; Lazzari, J. O.; Frasch, A. C.; Cazzulo, J. J.; Krishna, S. The trypanosomiases. Lancet, 2003, 362, 1469-1480.
17. Barrett, M. P.; Boykin, D. W.; Brun, R.; Tidwell, R. R. Human African trypanosomiasis: Pharmacological re-engagement with a neglected disease. Br. J. Pharmacol., 2007, 152, 1155-1171.
18. Brun, R.; Blum, J.; Chappuis, F.; Burri, C. Human African trypanosomiasis. Lancet, 2010, 375, 148-159.
19. Sánchez-Sancho, F.; Campillo, N. E.; Páez, J. A. Chagas disease: Progress and new perspectives. Curr. Med. Chem., 2010, 17, 423-452.
20. Coura, J. R.; Borges-Pereira, J. Chagas disease: 100 Years after its discovery. A systemic review. Acta Trop., 2010, 115, 5-13.
21. Urbina, J. A. Specific chemotherapy of Chagas disease: Relevance, current limitations and new approaches. Acta Trop., 2010, 115, 55-68.
22. Coura, J. R.; Albajar Viñas, P. Chagas disease: A new worldwide challenge. Nature, 2010, 465, S6-S7.
23. Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee. World Health Organ. Tech. Rep. Ser., 1998, 881, I-VI, 1-114.
24. Croft, S. L.; Barrett, M. P.; Urbina, J. A. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol., 2005, 21, 508-512.
25. Croft, S. L.; Engel, J. Miltefosine-discovery of the antileishmanial activity of phospholipid derivatives. Trans. R. Soc. Trop. Med. Hyg., 2006, 100 (Suppl 1), S4-8.
26. Sundar, S.; Jha, T. K.; Thakur, C. P.; Bhattacharya, S. K.; Rai, M. Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg., 2006, 100 (Suppl 1), S26-33.
27. Machado, P. R.; Ampuero, J.; Guimaraes, L. H.; Villasboas, L.; Rocha, A. T.; Schriefer, A.; Sousa, R. S.; Talhari, A.; Penna, G.; Carvalho, E. M. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: A randomized and controlled trial. PLoS Negl. Trop. Dis., 2010, 4, e912.
28. Yun, O.; Priotto, G.; Tong, J.; Flevaud, L.; Chappuis, F. NECT is next: Implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness. PLoS Negl. Trop. Dis., 2010, 4, e720.
29. Chakravarty, J.; Sundar, S. Drug resistance in leishmaniasis. J. Glob. Infect. Dis., 2010, 2, 167-716.
30. Ehrlich, P. Chemotherapeutics: Scientific principles, methods, and results. Lancet, 1913, 2, 445-451.
31. Eliopoulos, G. M.; Moellering, R. C., Jr. Antibiotic synergism and antimicrobial combinations in clinical infections. Rev. Infect. Dis., 1982, 4, 282-293.
32. Palella, F. J., Jr.; Delaney, K. M.; Moorman, A. C.; Loveless, M. O.; Fuhrer, J.; Satten, G. A.; Aschman, D. J.; Holmberg, S. D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med., 1998, 338, 853-860.
33. Nosten, F.; van Vugt, M.; Price, R.; Luxemburger, C.; Thway, K. L.; Brockman, A.; McGready, R.; ter Kuile, F.; Looareesuwan, S.; White, N. J. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: A prospective study. Lancet, 2000, 356, 297-302.
34. Priotto, G.; Fogg, C.; Balasegaram, M.; Erphas, O.; Louga, A.; Checchi, F.; Ghabri, S.; Piola, P. Three drug combinations for latestage Trypanosoma brucei gambiense sleeping sickness: A randomized clinical trial in Uganda. PLoS Clin. Trials, 2006, 1, e39.
35. Priotto, G.; Kasparian, S.; Mutombo, W.; Ngouama, D.; Ghorashian, S.; Arnold, U.; Ghabri, S.; Baudin, E.; Buard, V.; Kazadi- Kyanza, S.; Ilunga, M.; Mutangala, W.; Pohlig, G.; Schmid, C.; Karunakara, U.; Torreele, E.; Kande, V. Nifurtimoxeflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: A multicentre, randomised, phase III, non-inferiority trial. Lancet, 2009, 374, 56-64.
36. van Griensven, J.; Balasegaram, M.; Meheus, F.; Alvar, J.; Lynen, L.; Boelaert, M. Combination therapy for visceral leishmaniasis. Lancet Infect. Dis., 2010, 10, 184-194.
37. Sundar, S.; Rai, M.; Chakravarty, J.; Agarwal, D.; Agrawal, N.; Vaillant, M.; Olliaro, P.; Murray, H. W. New treatment approach in Indian visceral leishmaniasis: Single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin. Infect. Dis., 2008, 47, 1000-1006.
38. Sundar, S.; Mondal, D.; Rijal, S.; Bhattacharya, S.; Ghalib, H.; Kroeger, A.; Boelaert, M.; Desjeux, P.; Richter-Airijoki, H.; Harms, G. Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal-the challenges for diagnosis and treatment. Trop. Med. Int. Health, 2008, 13, 2-5.
39. Coura, J. R. Present situation and new strategies for Chagas disease chemotherapy: A proposal. Mem. Inst. Oswaldo Cruz, 2009, 104, 549-554.
40. Ndiaye, J. L.; Randrianarivelojosia, M.; Sagara, I.; Brasseur, P.; Ndiaye, I.; Faye, B.; Randrianasolo, L.; Ratsimbasoa, A.; Forlemu, D.; Moor, V. A.; Traore, A.; Dicko, Y.; Dara, N.; Lameyre, V.; Diallo, M.; Djimde, A.; Same- Ekobo, A.; Gaye, O. Randomized, multicentre assessment of the efficacy and safety of ASAQ-a fixeddose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria. Malar. J., 2009, 8, 125.
41. Asante, K. P.; Owusu, R.; Dosoo, D.; Awini, E.; Adjei, G.; Amenga Etego, S.; Chandramohan, D.; Owusu-Agyei, S. Adherence to artesunate-amodiaquine therapy for uncomplicated malaria in rural Ghana: A randomised trial of supervised versus unsupervised drug administration. J. Trop. Med., 2009, 2009, 529-583.
42. Panchagnula, R.; Agrawal, S.; Ashokraj, Y.; Varma, M.; Sateesh, K.; Bhardwaj, V.; Bedi, S.; Gulati, I.; Parmar, J.; Kaul, C. L.; Blomberg, B.; Fourie, B.; Roscigno, G.; Wire, R.; Laing, R.; Evans, P.; Moore, T. Fixed dose combinations for tuberculosis: Lessons learned from clinical, formulation and regulatory perspective. Methods Find. Exp. Clin. Pharmacol., 2004, 26, 703-721.
43. Nicoletti, S.; Seifert, K.; Gilbert, I. H. Water-soluble polymer-drug conjugates for combination chemotherapy against visceral leishmaniasis. Bioorg. Med. Chem., 2010, 18, 2559-2265.
44. Almeida de Silva, P.; Ainsa, J. A. In: Drugs and Drug Interactions. Tuberculosis 2007. From basic science to patient care; Palomino J.C. L. S. C.; Ritacco V. Ed. 2007; pp 593-633.
45. Hopkins, A. L.; Mason, J. S.; Overington, J. P. Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol., 2006, 16, 127-136.
46. Zimmermann, G. R.; Lehar, J.; Keith, C. T. Multi-target therapeutics: When the whole is greater than the sum of the parts. Drug Discov. Today, 2007, 12, 34-42.
47. Reddy, M.; Gill, S. S.; Kalkar, S. R.; Wu, W.; Anderson, P. J.; Rochon, P. A. Oral drug therapy for multiple neglected tropical diseases: A systematic review. JAMA, 2007, 298, 1911-1924.
48. Rybniker, J.; Goede, V.; Mertens, J.; Ortmann, M.; Kulas, W.; Kochanek, M.; Benzing, T.; Arribas, J. R.; Fatkenheuer, G. Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV- positive patient with chronic renal failure- a case report and brief review of the literature. Int. J. Infect. Dis., 2010, 14, e522-525.
49. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discov. Today, 2004, 9, 641-651.
50. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem., 2005, 48, 6523-6543.
51. Bakker, B. M.; Krauth-Siegel, R. L.; Clayton, C.; Matthews, K.; Girolami, M.; Westerhoff, H. V.; Michels, P. A.; Breitling, R.; Barrett, M. P. The silicon trypanosome. Parasitology, 2010, 137, 1333-1341.
52. Gerpe, A.; Odreman-Núñez, I.; Draper, P.; Boiani, L.; Urbina, J. A.; González, M.; Cerecetto, H. Heteroallyl-containing 5- nitrofuranes as new anti- Trypanosoma cruzi agents with a dual mechanism of action. Bioorg. Med. Chem., 2008, 16, 569-577.
53. Gerpe, A.; Boiani, L.; Hernández, P.; Sortino, M.; Zacchino, S.; González, M.; Cerecetto, H. Naftifine-analogues as anti- Trypanosoma cruzi agents. Eur. J. Med. Chem., 2010, 45, 2154-2164.
54. Graebin, C. S.; Madeira Mde, F.; Yokoyama-Yasunaka, J. K.; Miguel, D. C.; Uliana, S. R.; Benitez, D.; Cerecetto, H.; González, M.; Rosa, R. G.; Eifler- Lima, V. L. Synthesis and in vitro activity of limonene derivatives against Leishmania and Trypanosoma. Eur. J. Med. Chem., 2010, 45, 1524-1528.
55. Álvarez, G.; Gerpe, A.; Benítez, D.; Garibotto, F.; Zacchino, S.; Graebin, C. S.; da Rosa, R. G.; Eifler-Lima, V. L.; Gonzalez, M.; Cerecetto, H. New limonene-hybrid derivatives with anti-T. cruzi activity. Lett. Drug Des. Discov., 2010, 7, 452-460.
56. Viegas-Junior, C.; Danuello, A.; da Silva Bolzani, V.; Barreiro, E. J.; Fraga, C. A. Molecular hybridization: A useful tool in the design of new drug prototypes. Curr. Med. Chem., 2007, 14, 1829-1852.
57. del Rey, B.; Ramos, A. C.; Caballero, E.; Inchaustti, A.; Yaluff, G.; Medarde, M.; Rojas de Arias, A.; San Feliciano, A. Leishmanicidal activity of combretastatin analogues and heteroanalogues. Bioorg. Med. Chem. Lett., 1999, 9, 2711-2714.
58. Riente, R. R.; Souza, V. P.; Carvalho, S. A.; Kaiser, M.; Brun, R.; da Silva, E. F. Leishmanicidal activity of new megazol derivatives. Med. Chem., 2009, 5, 392-397.
59. Enanga, B.; Ariyanayagam, M. R.; Stewart, M. L.; Barrett, M. P. Activity of megazol, a trypanocidal nitroimidazole, is associated with DNA damage. Antimicrob. Agents Chemother., 2003, 47, 3368-3370.
60. Barrett, M. P.; Gilbert, I. H. Targeting of toxic compounds to the trypanosome's interior. Adv. Parasitol., 2006, 63, 125-183.
61. Luscher, A.; de Koning, H. P.; Maser, P. Chemotherapeutic strategies against Trypanosoma brucei: Drug targets vs. drug targeting. Curr. Pharm. Des., 2007, 13, 555-567.
62. Sands, M.; Kron, M. A.; Brown, R. B. Pentamidine: A review. Rev. Infect. Dis., 1985, 7, 625-634.
63. Navarro, M.; Gabbiani, C.; Messori, L.; Gambino, D. Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: Recent achievements and perspectives. Drug Discov. Today, 2010, 15, 1070-1078.
64. Morphy, R.; Rankovic, Z. Designing multiple ligands - medicinal chemistry strategies and challenges. Curr. Pharm. Des., 2009, 15, 587-600.